New three-year data for Roche’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA) April 29, 2022April 29, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: Roche’s Evrysdi (risdiplam) granted FDA priority…Roche’s Evrysdi (risdiplam) granted FDA priority…New data for Roche’s Evrysdi (risdiplam) demonstrate…FDA approves Roche’s Evrysdi for use in babies under…Positive new data for Roche’s Evrysdi in largest…Roche's Kadcyla is the first targeted therapy…
